• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:MDMA)

0.1000 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MDMA

< Previous 1 2 Next >
News headline image
Cortexa Advances Commercialisation of MDMA Supply in Australia
March 23, 2026
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla To Supply Østfold Hospital Trust with LaNeo™ MDMA for Clinical Research
January 08, 2026
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
December 15, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th
October 17, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
October 02, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
Small Cap Growth Virtual Investor Conference Agenda Announced for October 16th
October 14, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
June 03, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Contracts with Partner to Act as US Distributor
March 24, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
February 27, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
February 06, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
January 20, 2025
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024
From PharmAla Biotech
Via GlobeNewswire
News headline image
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
From PharmAla Biotech
Via GlobeNewswire
News headline image
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
From PharmAla Biotech
Via GlobeNewswire
News headline image
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024
Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications 
From PharmAla Biotech
Via GlobeNewswire
News headline image
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024
PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market 
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
January 24, 2024
New ticker symbol goes into effect immediately 
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024
PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in San Francisco 
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Begins Trading on OTCQB
September 06, 2023
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
July 31, 2023
Patent Filing Follows Year of Preclinical Research, Academic Publication 
From PharmAla Biotech
Via GlobeNewswire
News headline image
Life Science Investor Forum: Presentations Now Available for Online Viewing
June 23, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Investor Forum Agenda Announced for June 22nd
June 20, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
June 09, 2023
From PharmAla Biotech
Via GlobeNewswire
News headline image
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
May 01, 2023
From PharmAla Biotech
Via GlobeNewswire
News headline image
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
February 06, 2023
From Revive Therapeutics Ltd.
Via GlobeNewswire
News headline image
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
February 03, 2023
PharmAla Biotech is the only company in the world with the ability to ship GMP MDMA and Psilocybin today 
From PharmAla Biotech
Via GlobeNewswire
News headline image
The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News
January 27, 2023
Via ACCESSWIRE
News headline image
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
December 16, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap